Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer
New preclinical results support self-amplifying vRNA/LNP immunotherapy platform and ongoing IND-enabling studies of ONCR-021ANDOVER, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE)...